These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 31004722

  • 1. Immunization of mice by the co-administration of codon-optimized HPV16 E7 and lL12 genes against HPV16-associated cervical cancer.
    Ajorloo M, Alamdary A, Soleimanjahi H, El Boulani A, Khanizadeh S, Nikoo HR.
    Microb Pathog; 2019 Jul; 132():20-25. PubMed ID: 31004722
    [Abstract] [Full Text] [Related]

  • 2. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH, Roden RBS, Wu TC, Chang YN, Hung CF.
    mBio; 2021 Jan 19; 12(1):. PubMed ID: 33468698
    [Abstract] [Full Text] [Related]

  • 3. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S, Mohebbi A, Vakilzadeh G, Biglari P, Razeghi Jahromi S, Mohebi SR, Shirian S, Gorji A, Ghaemi A.
    Arch Virol; 2018 Mar 19; 163(3):587-597. PubMed ID: 29149434
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.
    Ohlschläger P, Quetting M, Alvarez G, Dürst M, Gissmann L, Kaufmann AM.
    Int J Cancer; 2009 Jul 01; 125(1):189-98. PubMed ID: 19358269
    [Abstract] [Full Text] [Related]

  • 6. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
    Cheung YK, Cheng SC, Sin FW, Xie Y.
    Vaccine; 2004 Dec 16; 23(5):629-38. PubMed ID: 15542183
    [Abstract] [Full Text] [Related]

  • 7. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S, Saeidi M, Fotouhi F, Mondanizadeh M, Shirian S, Mohebi A, Gorji A, Ghaemi A.
    Arch Virol; 2017 Feb 16; 162(2):333-346. PubMed ID: 27699512
    [Abstract] [Full Text] [Related]

  • 8. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
    Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S.
    Scand J Immunol; 2012 Jan 16; 75(1):27-37. PubMed ID: 21916914
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Antitumor Immunity Induced by Genetic Immunization with Chitosan Nanoparticle Formulated Adjuvanted for HPV-16 E7 DNA Vaccine.
    Tahamtan A, Barati M, Tabarraei A, Mohebbi SR, Shirian S, Gorji A, Ghaemi A.
    Iran J Immunol; 2018 Dec 16; 15(4):269-280. PubMed ID: 30593741
    [Abstract] [Full Text] [Related]

  • 11. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
    Sin JI.
    Immunology; 2009 Sep 16; 128(1 Suppl):e707-17. PubMed ID: 19740332
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY, Xu YF, Fan DS, Peng QL, Zhang T, Xu XM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct 16; 29(5):584-91. PubMed ID: 18051710
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice.
    Ren F, Xu Y, Mao L, Ou R, Ding Z, Zhang X, Tang J, Li B, Jia Z, Tian Z, Ni B, Wu Y.
    Cancer Biol Ther; 2010 Jan 16; 9(2):134-41. PubMed ID: 19901562
    [Abstract] [Full Text] [Related]

  • 16. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL, Qiu XH, Shen C, Liu JN, Zhang J.
    Oncol Rep; 2010 Nov 16; 24(5):1323-9. PubMed ID: 20878127
    [Abstract] [Full Text] [Related]

  • 17. A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner.
    Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL, Jiao XA.
    Front Cell Infect Microbiol; 2017 Nov 16; 7():279. PubMed ID: 28706878
    [Abstract] [Full Text] [Related]

  • 18. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J, Yin R, Tian Y, Huang Z, Shi J, Fu X, Wang L, Wu Y, Hao F, Ni B.
    Vaccine; 2012 Feb 01; 30(6):1071-82. PubMed ID: 22178528
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C, Dey B, Wahiduzzaman M, Singh N.
    Vaccine; 2012 Aug 03; 30(36):5417-24. PubMed ID: 22717329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.